噻托溴铵粉雾剂治疗慢性阻塞性肺病31例疗效观察

Clinical efficacy of tiotropium bromide powder in the treatment of patients with chronic obstructive pulmonary diseases

目的观察噻托溴铵粉雾剂治疗慢性阻塞性肺病(COPD)的临床效果及其安全性。方法 62例COPD患者随机分为观察组与对照组,各31例,观察组给予噻托溴铵粉雾剂吸入治疗,对照组使用爱全乐气雾剂(异丙托溴铵)吸入治疗,对比两组治疗前后临床症状、体征改善情况、肺功能变化以及治疗过程中的不良反应。结果观察组症状体征改善率(80.6%)显著高于对照组(54.8%)(P<0.05);观察组治疗后6周及12周FEV1、FVC均显著高于治疗前(P<0.05),而对照组则未见显著变化(P>0.05),且治疗后6周及12周观察组FEV1、FVC均显著高于对照组(P<0.05),两组FEV1/FVC在治疗前后均无明显变化(P>0.05);治疗过程中两组患者均未出现明显严重不良反应。结论噻托溴铵粉雾剂用于COPD的治疗疗效确切,安全可靠。

Objective To investigate the clinical efficacy of tiotropium bromide powder in the treatment of patients with chronic obstructive pulmonary diseases （COPD）. Methods Sixty-two patients with COPD were ran- domly divided into the study group （n=31） and the control group （n=31）. Tiotropium bromide powder was applied in the study group, and ipratropium bromide was used in the control group. The clinical symptoms and signs, lung func- tion, and the adverse reactions during the treatment were compared between the two groups. Results The improve- ment rate of the clinical symptoms and signs in the study group （80.6%） was significantly higher than that in the con- trol group （54.8%）,/~〈0.05. FEVI, FVC after treatment was significantly higher than before in the study group （P〈 0.05）; The FEV1, FVC in the study group was significantly higher six weeks and twelve weeks after treatment than those before treatment （P〈0.05）, while those in the control group showed no statistically significant difference after treatment （P〉0.05）. The FEVI, FVC were significantly higher in the study group than the control group after treat- ment. No statistically significant difference was found in FEVI/FVC in the two groups after treatment. There was no serious adverse reaction in the two groups during the treatment, Conelusion Tiotropium bromide powder is effec- tive, safe and reliable for treating patients with COPD.